healthcare-costs

  • |

    Public Grants, Private Tollbooth: Who Pays Twice for Xtandi?

    ByPhil McCracken

    At my invoice desk, the Xtandi money trail arrives wearing a lab coat and leaves in a limousine. The complaint is straightforward: public funding helped support UCLA-linked research, while commercialization and patent control became associated with Astellas and Pfizer. Then patients encountered annual U.S. price claims reaching roughly $160,000 to $180,000. That is a remarkable billing arrangement—taxpayers help finance the road, private interests control the toll gate, and the patient gets charged for driving on it.

    Not every stage of Xtandi’s development can be reduced to one public grant or one private decision, and a list price is not the same as every patient’s bill. But the public-return question remains as stubborn as a bad line item: when public science helps move an essential medicine forward, what does the public receive besides another invoice? Innovation may begin as public service, yet somehow ends as private property with a collections department. Follow the invoice long enough and it reaches the same destination: the patient, standing at the pharmacy counter with the receipt and no lobbyist’s expense account.

  • |

    Medicare’s Taxpayer-Funded Layaway Plan

    ByHarlan Quill

    At the courthouse-basement level of policy math, the arrangement is hard to defend: taxpayers help absorb the early risk of medical discovery, then a private patent can put the finished medicine behind a padlock while Medicare and patients meet the checkout price.

    That is a taxpayer-funded layaway plan. We help finance the scientific groundwork, a company controls the bottle, and the public returns to retrieve its medicine with a bill wearing a shareholder-return hat. If public support helps make a breakthrough possible, public policy should at least ask what public value comes back. Otherwise, we did not merely buy the breakthrough; we rented it back from the company that put a padlock on the bottle.

  • |

    If Prices Can Fall Now, Who Approved the Old Ones?

    ByHarlan Quill

    I have spent enough time with budgets to know that when a Medicare drug price falls after negotiation, the old price deserves an audit—not a standing ovation. The usual sales pitch says Medicare must accept whatever number arrives in the envelope, as though drug pricing were a weather event and not a market with lawyers. Then bargaining happens, the bill gets smaller, and “impossible” suddenly develops a discount code.

    The exact before-and-after figures may be illustrative, and lower prices do not automatically shrink every patient’s copay. But the practical point survives the fine print: negotiation can reduce public spending and may ease the bill at the pharmacy counter. The people defending the old system now have to explain why savings were forbidden until someone asked for them. The national drug-pricing spreadsheet has ruled that “unavoidable” was apparently the premium tier, complete with a lobbyist and no cancellation button.

  • |

    Follow the Money: When Medical Bills Wipe Out a Paycheck, the System Is Broken

    ByPhil McCracken

    I’m Phil McCracken, and I can tell when “care” turns into an accounts-receivable treadmill: getting sick shouldn’t mean going broke, yet premiums and deductibles keep showing up, then the Insurance Explanation of Benefits arrives like it’s done—until “another bill, another worry” turns into a collections-department vibe. One hospital bill later—$18,732.61, past due—and the paycheck is doing parkour instead of paying rent.

    That’s the contradiction the brochure won’t admit: “even insured” doesn’t mean protected, it means paperwork choreography—right up to the moment a medical bill can wipe out a paycheck and the whole system feels broken. So yeah, follow the money: who profits from making health care feel like a financial trap, instead of health care that should heal people, not bankrupt them.

  • |

    Help Wanted Isn’t a Path to Stability—It’s a Good-Job Shortage

    ByJustin Jest

    “Openings everywhere, stable life nowhere” isn’t a labor shortage—it’s a bookkeeping technique. The sign says “now hiring” like it’s a promise, but the fine print is basically: apply inside, then do math on rent, childcare, bus passes, and healthcare until your paycheck files for bankruptcy. The worker isn’t missing opportunity; they’re walking into a stability trapdoor with a name tag that reads “welcome aboard.”

    Follow the money and you find the real shortage: not people, but dependable pay, predictable schedules, and benefits that don’t require a side quest. “Good jobs” aren’t rare because workers disappeared—they’re rare because “help wanted” is being sold like a ladder when it’s actually just HR outsourcing the cost of survival. Someone should throw the whole sanitized story out the newsroom window with a Molotov made of receipts.

  • |

    If You’re Not Rich, Why Are You Defending the People Who Are?

    ByJustin Jest

    You think “they care about you?” Then the loyalty test starts: they busted unions. They shipped jobs overseas. They gave billionaires tax cuts. They let health care get pricier. They kept wages low. And you still think they’re fighting for you?

    Out in front of the Trump Gold Tower, they’re running the “VIP” branding like you’re the customer—“THANK YOU PRESIDENT TRUMP!” “YOU’RE THE BEST!”—while the placard reads “NO TAXES. NO RULES. ALL MINE.” So if you’re not rich, why are you defending the people who are, like the VIP section is real and your paycheck’s the one getting cut?

End of content

End of content